B+
Bull case
25%
Probability
Target price
$14.00
Analysis reference price unavailable
Analysis 2026-10-15 · RankAlpha Sentiment Codex
RNAC
Cartesian TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
A favorable AURORA readout could validate Descartes-08 in MG, while the five-patient retreatment observations offer limited supportive evidence of repeat-dosing potential [#8-K-2026-09-29]. The August company release reported approximately $149.3 million of cash, cash equivalents and restricted cash at June 30 and expected runway into 2028 [#SEC-8K-2026-08-06].
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +5.4.
What can break
AURORA may miss its placebo-controlled MG-ADL endpoint despite favorable small-cohort Phase 2 retreatment observations [#8-K-2026-09-29] [#SEC-8K-2026-08-06].
Momentum
12
Value
41
Sentiment
73
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $6.50 · Bull $14.00 · Bear $2.50Analysis 2026-10-15; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $33.67
Why
Momentum12 · Δ7d +2.9
Value41 · Δ7d -0.1
Sentiment73 · Δ7d +5.4
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +5.4.
Contradictions & invalidation
- • AURORA may miss its placebo-controlled MG-ADL endpoint despite favorable small-cohort Phase 2 retreatment observations [#8-K-2026-09-29] [#SEC-8K-2026-08-06].
- • Pipeline timelines and the company-stated runway into 2028 depend on trial execution and spending assumptions [#SEC-8K-2026-08-06].
- • The pivotal outcome remains binary.
Catalyst clock
2026-12-31
WestGene-partnered Phase 1 initiation
Lead driver: Sentiment · See AI snapshot
Momentum
12
8% active weight
Current posture
7d trendImproving
Δ7d
+2.9
Δ21d
+2.9
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.4
Sentiment
73
45% active weight
Current posture
7d trendImproving
Δ7d
+5.4
Δ21d
-17.5
Why this grade
Composite grade C. Momentum 11.8 / Value 40.6 / Sentiment 72.5
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-15. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$6.50
Analysis reference price unavailable
Analysis 2026-10-15 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$2.50
Analysis reference price unavailable
Analysis 2026-10-15 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$186.98M
Beta
0.45
Shares Out
30.26M
P/E (TTM) · Derived
-1.2
P/S (TTM)
93.25
P/FCF (TTM) · Derived
-2.14
Rev YoY
-100.0%
EPS YoY
-23.5%
Gross Margin
-76.6%
Op Margin
-5144.5%
Net Debt
-$112.46M
Current Ratio
7.48
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data